MedTrace Logo

Study of HS-10517 in Chinese Adult Participants

NCT05779579 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2023-04-03

No results posted yet for this study

Summary

A Phase I/II, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and primary efficacy of HS-10517 in Chinese adult participants.

Conditions

Interventions

DRUG

HS-10517 Dose 1

HS-10517 Dose 1+Ritonavir

DRUG

HS-10517 Dose 2

HS-10517 Dose 2+Ritonavir

DRUG

HS-10517 Dose 3

HS-10517 Dose 3+Ritonavir

DRUG

HS-10517 Dose 4

HS-10517 Dose 4+Ritonavir

DRUG

Placebo

Dose level A of placebo

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2023-05-31
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05779579 on ClinicalTrials.gov